当前位置:
X-MOL 学术
›
J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2020-02-20 , DOI: 10.1200/jco.2020.38.6_suppl.90 Xiaojian Qin 1 , Weiqing Han 2 , Hong Luo 3 , Chuanjun Du 4 , Qing Zou 5 , Zhongquan Sun 6 , Chaohong He 7 , Shaoxing Zhu 8 , Tie Chong 9 , Xin Yao 10 , Ben Wan 11 , Weijie Gu 12 , Dingwei Ye 12
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2020-02-20 , DOI: 10.1200/jco.2020.38.6_suppl.90 Xiaojian Qin 1 , Weiqing Han 2 , Hong Luo 3 , Chuanjun Du 4 , Qing Zou 5 , Zhongquan Sun 6 , Chaohong He 7 , Shaoxing Zhu 8 , Tie Chong 9 , Xin Yao 10 , Ben Wan 11 , Weijie Gu 12 , Dingwei Ye 12
Affiliation
90Background: SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinica...
中文翻译:
SHR3680,一种新型抗雄激素,用于治疗转移性去势抵抗性前列腺癌 (mCRPC):一项 I/II 期研究。
90 背景:SHR3680 是一种新型的纯雄激素受体 (AR) 拮抗剂,在临床前试验中,它对 CRPC 显示出有效的抗肿瘤活性,但脑分布比恩杂鲁胺少得多。
更新日期:2020-02-20
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
SHR3680,一种新型抗雄激素,用于治疗转移性去势抵抗性前列腺癌 (mCRPC):一项 I/II 期研究。
90 背景:SHR3680 是一种新型的纯雄激素受体 (AR) 拮抗剂,在临床前试验中,它对 CRPC 显示出有效的抗肿瘤活性,但脑分布比恩杂鲁胺少得多。